CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) fell 2.9% on Thursday after an insider sold shares in the company. The company traded as low as $42.78 and last traded at $42.22. 282,558 shares ...

The EU is to set to release a new class of genetically modified crops from strict regulation that dates back over 20 years, ...

CRISPR Therapeutics' stock faces challenges with slow Casgevy adoption and competition. See how CRSP stock remains a cautious ...

Bioengineering professor and The Grainger College of Engineering’s Dean, Rashid Bashir, led a team of researchers in a project that’s resulted in new technology that offers rapid, highly sensitive det ...

Researchers at Duke University and North Carolina State University have discovered a handful of new CRISPR-Cas systems that ...

The scientist who was jailed for three years for performing illegal gene-altering on babies has criticized ethics for slowing ...

University of Illinois at Urbana-Champaign researchers have developed a CRISPR-based diagnostic tool capable of detecting ...

A recent review published in the journal Engineering delves into the significant advancements and potential of CRISPR ...

The scientist who went to prison for gene hacking a pair of twins in China is now decrying the ethics that punished him.

A new review in Engineering reveals that CRISPR technologies are revolutionizing regenerative medicine. Scientists from ...

Shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) have been assigned a consensus recommendation of “Hold” from ...